Sermorelin vs. BPC-157, Ipamorelin & CJC-1295: How Peptides Differ

You'll often find sermorelin, BPC-157, ipamorelin, and CJC-1295 listed side by side. But this doesn't mean they're interchangeable.

Each one works differently in the body. Some have solid human research behind them, and others don't, and their legal status in the U.S. varies too. Below, we'll explore how each one works, what the research does (and doesn't) show, where each stands legally, and more.

‍

What These Peptides Have in Common, and Where They Diverge

All four are synthetic peptides, which means they're short chains of amino acids (the building blocks of proteins). Beyond that, the similarities somewhat end.

Essentially, these peptides fall within two groups:

1. GH peptides (sermorelin, ipamorelin, CJC-1295) work within your growth hormone system and signal the pituitary gland to release more growth hormone (GH).
2. Peptides studied for tissue-repair (BPC-157) have been explored for their potential effects on healing and inflammation, through pathways unrelated to GH.

In many ways, you can think of GH peptides as a signal to a factory to increase production, and BPC-157 as a repair crew sent to a specific job site. If you're new to the topic, our overview of how peptide therapy works may provide more insight.

‍

What Is Sermorelin?

Sermorelin is a synthetic peptide made from the first 29 amino acids of growth hormone-releasing hormone (GHRH), which is the hormone your hypothalamus uses to tell your pituitary gland to release GH. It's considered the shortest fragment that keeps GHRH's full biological activity.

When sermorelin binds to GHRH receptors on the pituitary, it prompts the gland to release its own growth hormone. Since sermorelin is cleared within minutes, this release comes in a brief pulse, similar to the body's natural rhythm. Your body's built-in brake, a hormone called somatostatin, also stays in play. And this preserved feedback loop is a mechanistic difference from injecting synthetic GH directly, a distinction sometimes discussed in relation to age-related changes in GH production.

Sermorelin was first FDA-approved in 1990 as Geref Diagnostic, used to test how well the pituitary releases GH, and in 1997 as Geref for treating certain children with growth hormone deficiency.

In a 16-week placebo-controlled study of adults aged 55 to 71, nightly injections of a GHRH analog increased GH and IGF-1 and increased lean body mass in men, though IGF-1 drifted back toward baseline by the end. A review of two six-month studies reported increased lean mass and modestly reduced body fat in healthy older adults. However, these findings do not establish the safety or effectiveness of compounded sermorelin for these outcomes.

Sermorelin's Regulatory and Access Status

Sermorelin's originally branded form, Geref products, are no longer made. The manufacturer stopped selling them in 2008.

Today, however, sermorelin may be available as a compounded medication prepared by state-licensed pharmacies when applicable compounding requirements are met and a licensed provider determines it is clinically appropriate. This is why telehealth platforms, like Eden's sermorelin program, offer a provider-led approach. Eden connects you with a licensed provider, who evaluates your current health status and determines what's best for you. You can also read our roundup of sermorelin reviews.

‍

What Is BPC-157?

BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid peptide described in the research literature as being derived from a sequence associated with a protein in gastric juice.

Researchers believe it may work in several ways. It may encourage new blood vessel formation (angiogenesis), influence nitric oxide pathways involved in inflammation and blood flow, and interact with growth factors tied to tissue repair, such as VEGF. These proposed mechanisms are why much of the research on BPC-157 focuses on tendon and ligament healing, gut protection, and local inflammation.

Yet, most BPC-157 research comes from animal models and cell studies. A 2025 systematic review of BPC-157 in orthopedic sports medicine found that 35 of the 36 studies it included were preclinical, with just one small human study. Animal studies have shown promising results, but large, well-designed human trials haven't been completed.

‍

BPC-157's Regulatory Status: What You Should Know

In 2023, the FDA flagged BPC-157 as a substance that may pose significant safety risks in compounding. In April 2026, it was moved to the FDA's list of nominated substances that were withdrawn, though the agency's notes still cite potential concerns about immune reactions and impurities.

In July 2026, an FDA advisory committee voted to recommend adding BPC-157 to the list of substances pharmacies can compound with. The vote is non-binding, and as of October 2026, a proposed interim access policy for certain peptides was still under White House review.

This means that, as of this writing, BPC-157 is not FDA-approved and doesn't currently have an established pathway for routine compounding under applicable federal requirements. In other words, it isn't currently offered through the same routine prescription-compounding pathway described for sermorelin. Since this area is continually changing, check with a licensed provider for the most current and up-to-date information.

‍

What Is Ipamorelin?

Ipamorelin is a growth hormone secretagogue (a compound that triggers GH release) from the growth hormone-releasing peptide (GHRP) family. When it comes to the difference between ipamorelin vs sermorelin, sermorelin mimics GHRH, but ipamorelin mimics ghrelin. This means it binds to the ghrelin receptor (GHS-R1a) to trigger GH release.

Ipamorelin is often described as "selective." In early animal research, it released GH without raising cortisol or prolactin the way older GHRPs, like GHRP-6, did. However, human data is limited to small pharmacology studies and trials for post-surgical gut recovery. It's sometimes paired with CJC-1295 because the two act on complementary receptors. But this doesn't establish the safety or effectiveness of that combination in humans.

Ipamorelin is not FDA-approved. In 2024, an FDA advisory committee reviewed ipamorelin and did not recommend adding it to the list of substances licensed pharmacies can compound with. The FDA has also noted serious adverse events, including a death, reported when it was given intravenously in a study. As of October 2026, it doesn't have an established pathway for routine compounding through licensed U.S. pharmacies.

‍

What Is CJC-1295?

CJC-1295 is a synthetic GHRH analog, meaning it's similar in concept to sermorelin. The difference is staying power. The version with Drug Affinity Complex (DAC) is chemically modified to bind to albumin, a protein in your blood, which dramatically slows its clearance.

In a study of healthy adults, one dose of CJC-1295 kept growth hormone levels elevated for six days or more. This is because its half-life is roughly six to eight days, while sermorelin clears from the body within minutes.

The two also differ in how they release growth hormone. Sermorelin causes a short burst, similar to your body's natural rhythm. With CJC-1295, the body's natural GH pulses still happen, but GH levels stay higher between them. This more sustained elevation, sometimes called a "GH bleed," is one of the main ways it differs from sermorelin.

When comparing CJC-1295 and sermorelin even further, regulatory factors and evidence also differ. CJC-1295 has been studied in only small human trials, isn't FDA-approved for any use, and an FDA advisory committee voted against adding it to the compounding list in 2024. The FDA also lists reported adverse events such as increased heart rate. It also doesn't have an established pathway for routine compounding through licensed U.S. pharmacies under current federal requirements.

Peptide Therapy Comparison: Sermorelin vs. BPC-157 vs. Ipamorelin vs. CJC-1295

This table is a reference tool, not a recommendation. It demonstrates why these peptides aren't interchangeable and why regulatory status is important for access. Always talk with a licensed provider before pursuing any peptide therapy.

‍

Can These Peptides Be Used Together?

Mechanically, sermorelin and BPC-157 target different systems, one hormonal and one tissue-focused. This means that they have different proposed mechanisms, although this doesn't establish that combining them is safe or beneficial. Sermorelin, ipamorelin, and CJC-1295 all aim at GH release but through different receptors or timelines, which is why combinations like ipamorelin plus CJC-1295 come up in discussions.

With that said, stacking peptides adds another layer of complexity. Using multiple GH-stimulating compounds may increase the risk of unintended hormonal effects, and several of these peptides lack strong human safety data or a legal compounding pathway. Combination protocols aren't standard or recommended, and any combination requires individualized evaluation by a licensed healthcare provider.

‍

Which Peptide May Be Right for You?

If your goal is understanding GH levels and age-related changes: Sermorelin is a peptide with a documented clinical history and human research, and it may be available by prescription through licensed providers when clinically appropriate. If you're working toward body composition goals, talk with a licensed provider about what's best for you.

If your goal is tissue repair, tendon or ligament healing, or gut support: BPC-157 is a peptide studied for these potential applications. However, it's mostly been explored in animals, and it isn't currently available through licensed U.S. compounding pharmacies.

If you're curious about GH secretagogue combinations: Ipamorelin and CJC-1295 often come up here, but neither has an established routine U.S. prescription-compounding pathway at this time.

If sermorelin sounds like a fit, Eden makes exploring your options simple. You'll complete a quick online intake, and a licensed provider will review your health history, goals, and current medications.